Iambic Therapeutics
PrivateLast Round
Series B
Sep 9, 2026
Total Funding Raised
$253M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Iambic Therapeutics is a biotechnology company that develops an AI-driven drug discovery platform to create novel medicines for cancer and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iambic Therapeutics Comparables
Compare Iambic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Therapeutics | 88% | |
| Valo Health | 87% | |
| Terray Therapeutics | 87% |
Iambic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 9, 2026 | ||||
| Early Stage VC | Apr 8, 2026 | ||||
| VC Round | Nov 10, 2025 | ||||
| Series B Extension | Jun 18, 2024 | ||||
| Series B | Oct 3, 2023 | ||||
Series A | Jul 14, 2021 |
Key People
Founding team and executive leadership
Iambic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B |
| OrbiMed | Series B, Series A |
| Catalio Capital Management | Series B, VC Round, Series A |
| Freeflow Ventures | VC Round |
| Sequoia Capital | Series B, Series A, VC Round |
| Abingworth | Series B Extension, VC Round, Series B |
| Shanda Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2026
$66M round closed.
- Aug 1, 2026
Grew 18% QoQ, from 146 to 172 employees.
Recent news
Latest coverage and updates
- is_developingSep 22, 2026
Iambic Therapeutics, Inc. is developing two earlier-stage programs designated IAM217 and IAM-C1 on Sep 21st '26.
- partners_withSep 22, 2026
Iambic Therapeutics, Inc. partnered with AbbVie Inc. on Sep 21st '26.
- launchesSep 21, 2026
Iambic Therapeutics, Inc. launches next generation of one of main AI models.
- launchesSep 21, 2026
Iambic Therapeutics, Inc. launches next version of Enchant model.
- goes_publicSep 21, 2026
Iambic Therapeutics, Inc. was planning to go public on Sep 21st '26.
Iambic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Iambic Therapeutics's valuation, stock price, and market status.
Is Iambic Therapeutics a public or private company?
Iambic Therapeutics is a private company.
What is the current stock price of Iambic Therapeutics?
Iambic Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Iambic Therapeutics worth (valuation)?
Valuation information for Iambic Therapeutics is not publicly available.
Can I buy Iambic Therapeutics stock?
Iambic Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Iambic Therapeutics's last funding round?
Iambic Therapeutics's most recent funding round was Early Stage VC on April 8, 2026.
Who are the main investors in Iambic Therapeutics?
Key investors in Iambic Therapeutics include Catalio Capital Management, Abingworth, Mubadala Capital, Exor Ventures, Ascenta Capital.
Will Iambic Therapeutics IPO soon?
No public IPO plans have been announced for Iambic Therapeutics.
How can I track Iambic Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Iambic Therapeutics's secondary market activity and sign up for updates.